ESR1 and breast cancer: Recently a synthetic curcumin analog, PAC (u4-hydroxy-3-methoxybenzylideneN-methyl-4-piperidone) exhibited higher bioavailability and potent anti-cancer activity and was demonstrated to downregulate estrogen receptor (ER) and EMT in breast cancer cells in vitro and in vivo [195,196].